Plain-English translation of NCT05455619 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new medication called combined with two standard breast cancer treatments (either alpelisib or capivasertib, plus fulvestrant). The goal is to see if adding this medication can prevent or reduce the blood sugar problems that often happen with these cancer drugs, while still fighting the cancer effectively.
When doctors use certain breast cancer medications that target a specific genetic pathway, patients often develop high blood sugar levels as a side effect. This can make the cancer treatment less effective and harder to tolerate. This trial is investigating whether the new treatment can prevent these blood sugar problems, helping patients stay on their cancer therapy longer and at better doses.
You likely qualify if…
You likely don't qualify if…
You would take the new medication by mouth in 28-day cycles, along with one of two standard breast cancer drugs and fulvestrant (which may be given as an injection). You would continue treatment as long as your cancer is responding and you are tolerating the medications well. Throughout the study, you would have regular visits for blood tests, imaging scans, and checkups to monitor how the treatment is working and to track your blood sugar levels.
AI-generated summary from trial data · Aug 20, 2026 · Not medical advice
United States